<DOC>
	<DOCNO>NCT01226901</DOCNO>
	<brief_summary>This study evaluate whether oral administration MK-4827 participant advance solid tumor generally safe well tolerate .</brief_summary>
	<brief_title>A Phase I Study MK-4827 Treatment Solid Tumors ( MK-4827-005 )</brief_title>
	<detailed_description />
	<mesh_term>Niraparib</mesh_term>
	<criteria>Participant must histologically cytologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist . There limit number prior treatment regimen . Participant performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Participant must adequate organ function ( per prespecified laboratory value ) . Participant major surgery , chemotherapy , radiotherapy , hormonal biological therapy within 4 week ( 6 week nitrosoureas , mitomycin C , bevacizumab ) prior enter study . Participant known central nervous system metastases primary central nervous system tumor . Participant pregnant breast feeding , expect conceive father child within project duration study . Participant known Human Immunodeficiency Virus ( HIV ) positive . Participant active Hepatitis B C. Participant symptomatic ascites pleural effusion . Participant interstitial lung disease history current evidence . Participant known bleeding tendency coagulation disorder history current evidence , and/or participant take anticoagulant and/or antiplatelet therapy . Participant uncontrolled persistent active infection ( acute infection require antibiotic antifungal treatment ) . Participant participate clinical trial know Poly ( ADPribose ) polymerase ( PARP ) inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Poly ( ADP-ribose ) polymerase ( PARP ) inhibitor</keyword>
	<keyword>tumor</keyword>
	<keyword>cancer</keyword>
</DOC>